EUCTR2016-005035-33-GB进行中（未招募）1 期
A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progressiva - LUMINA-1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women 18 to 60 years of age at screening.
- •2. Clinical diagnosis of FOP (based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive heterotopic ossification).
- •3. Confirmation of FOP diagnosis with documentation of any ACVR1 mutation.
- •4. FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, and other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of heterotopic ossifications (increase in site or number of HO lesions) with/without being associated with flare-up episodes.
- •5. Willing and able to undergo PET and CT imaging procedures and other procedures as defined in this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Significant concomitant illness or history of significant illness such as, but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study.
- •2. Use of bisphosphonate within 1 year of screening.
- •3. Concurrent participation in another interventional clinical study, or a non-interventional study with radiographic measures or invasive procedures (e.g. collection of blood or tissue samples). Participation in the FOP Connection Registry or other studies in which patients complete study questionnaires are allowed.
- •4. Pregnant or breastfeeding women.
- •5. Male and women of childbearing potential patients who are unwilling to practice highly effective contraception.
- •6. Previous history or diagnosis of cancer.
- •7. Patients who are on concomitant antiplatelet therapy (e.g., clopidogrel), anti-coagulants (e.g., warfarin, heparin, factor Xa inhibitor, or thrombin inhibitors) in the last 30 days or within 5 half-lives of the therapy, whichever is longer. Low dose (=100 mg/day) acetylsalicylic acid (aspirin) is acceptable.
- •8. Patients with a history of severe, non-traumatic bleeding requiring transfusion or hospitalization for hemodynamic compromise
- •9. Patients with a known pre-existing medical history of a bleeding diathesis (e.g., hemophilia A, von Willebrand’s Factor deficiency, platelet count =20x10^9/L).
研究者
相似试验
进行中（未招募）
1 期
A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-005035-33-ITREGENERON PHARMACEUTICALS, INC.44
进行中（未招募）
1 期
A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-005035-33-NLRegeneron Pharmaceuticals, Inc.40
进行中（未招募）
1 期
A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-005035-33-ESRegeneron Pharmaceuticals, Inc.44
已完成
2 期
A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaNL-OMON50623Regeneron Pharmaceuticals, Inc.6
尚未招募
Unknown
The combination of Berberis aristata and Phyllanthus emblica extract in the management of prediabetes.CTRI/2024/06/068301Pharmanza Herbal Pvt. Ltd